ASCIL-Biopharm-logo

Welcome to ASCIL Biopharm

ASCIL Biopharm develops proprietary miniaturized injectable and locally acting therapeutics with advanced Drug Delivery Systems (DDS) – formulations and medical devices – to enhance the safety, effectiveness and convenience of administration of drugs for chronic high burden diseases. 

Our fields of activity are Pharma, Biotech, Aesthetic and Veterinary Care Innovations.

A team with a track record of succes in drug delivery.

The company’s approach leverages the expertise of its highly experienced team,
which has pioneered the development of commercial controlled release therapeutics,
including peptides in long acting biodegradable and self-assembly DDS.

ASCIL-Biopharm-Cherif-Cheikh-Roland

Roland Chérif-Cheikh
Founder & CEO
Pioneer in peptide DDS

ASCIL-Biopharm-Lacombe-Frederic

Frédéric Lacombe
R&D Operations Director
Co-founder

ASCIL-Biopharm-Lachamp-Laurence

Laurence Lachamp
Business Innovation Director
Co-founder

The Team includes 20 scientists with a unique cluster of expertise and skills focused on drug product CMC, biopharmacy and delivery device innovation
The team has been working together for nearly 20 years, and is familiar to the highest industrial standards, in R&D small molecules, peptides and proteins DDS and biomed programs for biotech and pharma companies.

ASCIL BIOPHARM PORTFOLIO
Several clinical-ready products for partnering:

APOC

Novel controlled release drug product for Neuroendocrine Tumors (NETs) and Acromegaly.

ONYMED

Innovative long-acting miniaturized therapeutic to treat a wide range of nail diseases.

ascil-biopharm-icon-combo

COMBO

First product allowing non-fixed ratio injectable combo-therapies, without contact, in one shot.

ascil-biopharm-icon-astech

ASTECH

Family of facilitating prefilled devices designed to inject easily highly viscous to pasty products with extreme precision.

R&D PRECLINICAL INNOVATION PIPELINE
based on three axes of an integrated innovation:

PROFILE: Biopharmaceutical controlled release of formulations.

  • Formulations for up to quarterly administration of high dose biologics (>300mg/mL).
  • Immediate release ready-to-use DDS for emergency drugs and peptides for chronic use acting at mg scale.

FOCUS: Focused local action.

  • Intravitreal long-acting products.
  • Dermo-cosmetic targeted delivery technologies for skin health improvements.

ADAPT: New drug product-device combinations.

  • Ready-to-use lyophilized alternatives to dual-chamber options.
  • Transdermal technologies for minimally invasive delivery: Novel routes of administration.

The project “Un dispositiu mèdic com eina de millora terapèutica en malaltia de llarga durada” is cofunded by:

Logo-Feder-Ascil-Biopharm

HYBRID BUSINESS, focused on PRODUCT INNOVATION

ASCIL Biopharm creates innovative DDS (formulations and devices) in order to license them when the proof-of-concept is confirmed and the intellectual property covered. ASCIL Biopharm also partners with companies and institutions to develop new DDSs to sustain their pipelines and provide innovative solutions for their products.

pyme-innovadora-meic-EN-web

PREMISES

ASCIL Biopharm operates within the Barcelona Tech Science Park of the Polytechnical University of Catalonia (UPC) with 500 m² of GxP operational dedicated R&D+i facilities in Viladecans (Barcelona), including 5 laboratories.

Fully internal equipped laboratories to carry out activity in confidential environment.

@ 2 minutes from Barcelona international airport

CONTACT INFORMATION
Parc UPC- BarcelonaTech
Camí de les filipines 110
08840 Viladecans
Barcelona – Spain

+34934137922
info@ascil-biopharm.com

© 2018 ASCIL BIOPHARM | www.ascil-biopharm.com